Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Closes IPO Raising $184M

NEW YORK (GenomeWeb News) – Intrexon announced after the close of the market on Tuesday the closing of its initial public offering raising $184 million in gross proceeds.

The Germantown, Md.-based synthetic biology firm said it sold about 11.5 million shares of its common stock at $16 per share. About 10 million shares were sold as part of the initial offering, and another 1.5 million shares were sold to the underwriters of the offering as part of their overallotment option.

JP Morgan and Barclays were joint book-running managers on the offering. Griffin Securities and Mizuho Securities were co-managers.

Intrexon went public on Aug. 8.

In morning trading on the New York Stock Exchange, shares of Intrexon were down 6 percent at $27.03

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.